Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G VivasGynaecological oncology — gestational trophoblastic disease

O&G Vivas · Gynaecological oncology — gestational trophoblastic disease

Gestational trophoblastic neoplasia — structured oral station (12 minutes)

FRANZCOG oral-format station on post-molar gestational trophoblastic neoplasia: candidate makes the biochemical diagnosis, stages and scores with the FIGO 2000 system, defends single-agent methotrexate-folinic acid, and counsels on cure and fertility. Scored against the eight published RANZCOG oral domains.

clinical3 min readVerification in progress

Target exams

FRANZCOGMRCOGABOG
On this page
Study tools

Target exams

FRANZCOGMRCOGABOG
Prompt
You are the gynaecology registrar. A 30-year-old woman had a suction evacuation for a complete hydatidiform mole seven weeks ago and has used oral contraception since. Her serial serum hCG (IU/L) has plateaued over four weekly tests: 700, 730, 685, 715. She is otherwise well. The examiner will ask you to take this from the diagnosis through staging, scoring, treatment and counselling.

Station format

4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport; respect; communication skills.[3]

Reveal the examiner script and model responsesShowHide

Opening prompt — "What is the diagnosis, and what is your first action?"

Model response: [1][3]

  • "This is post-molar gestational trophoblastic neoplasia. The hCG has plateaued across four weekly values, meeting the FIGO plateau criterion for post-molar GTN."
  • "My first action is to confirm the hCG is real with a urine test — to exclude a phantom hCG — and to exclude a new pregnancy with ultrasound, since she is on contraception. Then I register her with the regional trophoblast centre and stage and score her."

Probe 1 — "Reproduce the FIGO 2000 anatomic staging."

  • "Stage I, disease confined to the uterine corpus; Stage II, disease extending outside the uterus but limited to the genital tract structures; Stage III, disease extending to the lungs with or without genital tract involvement; Stage IV, all other metastatic sites. The stage and the WHO score are written together as a single figure."[1][2]

Probe 2 — "Reproduce the WHO score variables and the cut-off."

  • "Eight variables: age; antecedent pregnancy; interval in months from the index pregnancy; pre-treatment serum hCG; largest tumour size including uterus; site of metastases; number of metastases identified; and previous failed chemotherapy. Each is scored 0, 1, 2 or 4."[2][3]
  • "A total of 6 or below is low-risk and gets single-agent chemotherapy; 7 or above is high-risk and gets multi-agent EMA-CO. The Charing Cross convention scores 0 to 8 as low-risk."[4]
  • "A 2026 FIGO revision exists — consult the current score table at the station for any variable-level changes."[7]

Probe 3 — "She is FIGO stage I with a WHO score of 3. What treatment do you give, and what do you tell her about the outcome?"

  • "Low-risk disease. I give the Charing Cross 8-day methotrexate-folinic acid regimen: methotrexate 50 mg intramuscularly on days 1, 3, 5 and 7, with folinic acid rescue on days 2, 4, 6 and 8, repeated every two weeks until hCG normalises and then for consolidation."[4][5]
  • "The McNeish Charing Cross cohort of 485 women reported 100% overall survival with this regimen; about two-thirds normalise on methotrexate alone. Actinomycin-D 1.25 mg per square metre every two weeks is the alternative if methotrexate is resisted or contraindicated."[4][5]

Probe 4 — "She is frightened and asks whether she will die, and whether she can have more children."

Counsel with the numbers — this is a scored domain: [3]

  • "This is one of the most curable cancers we treat — overall cure exceeds 95%, and your form is essentially always cured. Treatment preserves fertility, and most women conceive afterwards. I will keep a close eye on your hCG and support you through it."
  • Acknowledge her fear, give the numbers plainly, confirm she has understood, and arrange a point of contact.

Probe 5 — "What if her score had been 14, with liver metastases?"

  • "High-risk, ultra-high-risk disease. I would not start full-dose EMA-CO directly — I would begin with low-dose induction etoposide 100 mg per square metre and cisplatin 20 mg per square metre on days 1 and 2 weekly, to avoid fatal tumour lysis, then proceed to EMA-CO. The Alifrangis cohort showed induction cut the early-death rate from 7.2% to 0.7%, with 94.3% overall survival in high-risk disease."[6]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References7ShowHide
  1. [1]FIGO Oncology Committee FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet, 2002.PMID 12065144
  2. [2]Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet, 2003.PMID 14763174
  3. [3]Soper JT Gestational Trophoblastic Disease: Current Evaluation and Management. Obstet Gynecol, 2021.PMID 33416290
  4. [4]McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, Newlands ES Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol, 2002.PMID 11919242
  5. [5]Jiang F, Guan CL, Jiao LZ, Xu T, Wan XR, Shi SS, et al. Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial. Ann Oncol, 2025.PMID 40543844
  6. [6]Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol, 2013.PMID 23233709
  7. [7]Ngan HYS, Seckl MJ, Horowitz N, Cheung ANY, Braga A, Sekharan PK, Fridsten S, Garrett A, Yanaihara N, Wilailak S, Schmalfeldt B FIGO staging for gestational trophoblastic neoplasia: 2026 Int J Gynaecol Obstet, 2026.PMID 42473063
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousGestational trophoblastic disease — structured oral station (12 minutes)Early pregnancy care — gestational trophoblastic diseaseNextPost-molar gestational trophoblastic neoplasia — structured oral station (12 minutes)Gynaecological oncology — gestational trophoblastic disease